Well autophagy and inflammation could possibly cover a swag of neurological conditions IMO. So that still leaves PYC with heaps of possible targets.
Sheet, even getting the RP11 single treatment out opens the sluices to a river of $$$$.
But I guess investors will take the worst out of the webinar and sell the crap out of it and grind the price down for months and months. We’ll be back in the 3’s before the clinical trial results are in.
PYC, page-46
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.0¢ |
Change
-0.005(4.35%) |
Mkt cap ! $513.2M | |||
| Open | High | Low | Value | Volume |
| 11.5¢ | 11.8¢ | 11.0¢ | $297.5K | 2.621M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 1372418 | 11.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.5¢ | 390472 | 6 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| PYC (ASX) Chart |